Rui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui Liu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Baojin Hua
Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
5 shared publications Yue Li
4 shared publications- Baojin Hua
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China
3 shared publications - Qiujun Guo
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No.5, Beixiange Road, Xicheng District, Beijing, 100053, China
2 shared publications - Runzhi Qi
Department of Oncology, Academy of Chinese Medical Sciences, Guang’anmen Hospital, China , Beijing, China
2 shared publications Yue Luo
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2195
Cancer-Related Psychological Distress over the Past Decade: A Bibliometric Analysis of Research Trends, Hotspots, and Emerging Areas
Background: Cancer-related psychological distress is a major concern in comprehensive oncology care because it substantially impairs patients’ quality of life and may adversely affect treatment adherence, outcomes, and prognosis. Over the past decade, research in this field has expanded rapidly; however, the overall knowledge structure, global research patterns, major contributors, and emerging hotspots remain insufficiently characterized. A bibliometric analysis is therefore needed to systematically map the development of cancer-related psychological distress research and identify evolving directions for future investigation. Methods: Publications related to cancer-related psychological distress published between 1 January 2015 and 31 December 2024 were retrieved from the Web of Science Core Collection and Scopus databases. The database searches were conducted on 10 March 2025. Bibliometric analyses were performed using VOSviewer (version 1.6.20), CiteSpace (version 6.3.R1), and the R package bibliometrix (version 5.3). Publication trends, country and institutional contributions, journal distribution, author collaboration networks, co-cited references, keyword co-occurrence, burst keywords, and thematic evolution were analyzed. Results: A total of 7063 publications were included in the bibliometric analysis, including 6162 articles and 901 reviews. Annual publication output increased from 465 publications in 2015 to 924 publications in 2024. The main contributing countries were the United States, Australia, China, Germany, and the United Kingdom. The United States ranked first in publication volume and total citations. Psycho-Oncology and Supportive Care in Cancer were the leading journals by publication volume and total citations. Major research themes included quality of life, psychological distress, depression, anxiety, breast cancer, distress screening, survivorship, and palliative care. Seven high-frequency keywords—“cancer,” “quality of life,” “psychological distress,” “depression,” “anxiety,” “breast cancer,” and “distress”—each appeared more than 500 times, representing the core research topics. Emerging keywords such as “informal caregivers,” “young adults,” “guidelines,” and “adult survivors” reflected increasing attention to caregiver support, age-specific psychosocial needs, survivorship care, and standardized clinical management. Conclusions: This bibliometric analysis provides a comprehensive overview of global research on cancer-related psychological distress from 2015 to 2024. The findings reveal publication trends, major contributors, collaboration patterns, core research themes, knowledge structures, and emerging topics in this field. Current research has gradually shifted from general descriptions of psychological distress toward survivorship care, caregiver support, standardized screening, and guideline-based management. Future studies should strengthen interdisciplinary collaboration, improve standardized assessment and screening approaches, and further explore emerging areas such as caregiver support, young adult cancer populations, survivorship care, and digital health and artificial intelligence-assisted approaches, which require further validation before routine clinical implementation.
- 20 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2195
Open AccessCancer-Related Psychological Distress over the Past Decade: A Bibliometric Analysis of Research Trends, Hotspots, and Emerging Areas
Background: Cancer-related psychological distress is a major concern in comprehensive oncology care because it substantially impairs patients’ quality of life and may adversely affect treatment adherence, outcomes, and prognosis. Over the past decade, research in this field has expanded rapidly; however, the overall knowledge structure, global research patterns, major contributors, and emerging hotspots remain insufficiently characterized. A bibliometric analysis is therefore needed to systematically map the development of cancer-related psychological distress research and identify evolving directions for future investigation. Methods: Publications related to cancer-related psychological distress published between 1 January 2015 and 31 December 2024 were retrieved from the Web of Science Core Collection and Scopus databases. The database searches were conducted on 10 March 2025. Bibliometric analyses were performed using VOSviewer (version 1.6.20), CiteSpace (version 6.3.R1), and the R package bibliometrix (version 5.3). Publication trends, country and institutional contributions, journal distribution, author collaboration networks, co-cited references, keyword co-occurrence, burst keywords, and thematic evolution were analyzed. Results: A total of 7063 publications were included in the bibliometric analysis, including 6162 articles and 901 reviews. Annual publication output increased from 465 publications in 2015 to 924 publications in 2024. The main contributing countries were the United States, Australia, China, Germany, and the United Kingdom. The United States ranked first in publication volume and total citations. Psycho-Oncology and Supportive Care in Cancer were the leading journals by publication volume and total citations. Major research themes included quality of life, psychological distress, depression, anxiety, breast cancer, distress screening, survivorship, and palliative care. Seven high-frequency keywords—“cancer,” “quality of life,” “psychological distress,” “depression,” “anxiety,” “breast cancer,” and “distress”—each appeared more than 500 times, representing the core research topics. Emerging keywords such as “informal caregivers,” “young adults,” “guidelines,” and “adult survivors” reflected increasing attention to caregiver support, age-specific psychosocial needs, survivorship care, and standardized clinical management. Conclusions: This bibliometric analysis provides a comprehensive overview of global research on cancer-related psychological distress from 2015 to 2024. The findings reveal publication trends, major contributors, collaboration patterns, core research themes, knowledge structures, and emerging topics in this field. Current research has gradually shifted from general descriptions of psychological distress toward survivorship care, caregiver support, standardized screening, and guideline-based management. Future studies should strengthen interdisciplinary collaboration, improve standardized assessment and screening approaches, and further explore emerging areas such as caregiver support, young adult cancer populations, survivorship care, and digital health and artificial intelligence-assisted approaches, which require further validation before routine clinical implementation.
- Open Access
- 13 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10218-10242
The intersection of artificial intelligence and lung nodule research: current applications and future prospects
Lung cancer represents a primary global cause of cancer-related mortality, imposing substantial healthcare burdens on both patients and public health systems. Pulmonary nodules, as early-stage manifestations of lung cancer, exhibit considerable morphological heterogeneity. Consequently, precise identification and clinical management of these nodules are critical for effective lung cancer prevention. In recent years, artificial intelligence (AI) has emerged as a transformative component in modern oncology, providing advanced tools for end-to-end pulmonary nodule management. This review systematically analyzes existing literature through bibliometric assessment to synthesize AI applications across the pulmonary nodule care continuum. AI-powered clinical decision support systems and personalized treatment planning are reshaping precision oncology paradigms. Current research advancements and prevailing challenges are critically examined to identify potential future breakthroughs. The comprehensive synthesis presented herein aims to establish a foundational conceptual framework for researchers and clinicians, while facilitating efficient translation of AI technologies into clinical practice for pulmonary nodule diagnosis and therapy.
- 13 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10218-10242
Open AccessThe intersection of artificial intelligence and lung nodule research: current applications and future prospects
Lung cancer represents a primary global cause of cancer-related mortality, imposing substantial healthcare burdens on both patients and public health systems. Pulmonary nodules, as early-stage manifestations of lung cancer, exhibit considerable morphological heterogeneity. Consequently, precise identification and clinical management of these nodules are critical for effective lung cancer prevention. In recent years, artificial intelligence (AI) has emerged as a transformative component in modern oncology, providing advanced tools for end-to-end pulmonary nodule management. This review systematically analyzes existing literature through bibliometric assessment to synthesize AI applications across the pulmonary nodule care continuum. AI-powered clinical decision support systems and personalized treatment planning are reshaping precision oncology paradigms. Current research advancements and prevailing challenges are critically examined to identify potential future breakthroughs. The comprehensive synthesis presented herein aims to establish a foundational conceptual framework for researchers and clinicians, while facilitating efficient translation of AI technologies into clinical practice for pulmonary nodule diagnosis and therapy.
- Open Access
- 19 December 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 194, 118927
Mitochondria-targeted nanosystem-mediated delivery of cryptotanshinone for enhanced suppression of non-small cell lung cancer
- 19 December 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 194, 118927
Open AccessMitochondria-targeted nanosystem-mediated delivery of cryptotanshinone for enhanced suppression of non-small cell lung cancer
- Open Access
- 4 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1553-1579
Worldwide research on 3D printing for cancer: a dual-method analysis of bibliometrics and stratified focused thematic
Aim: This study investigates the application of three-dimensional (3D) printing in cancer research and treatment, highlighting the current advancements, key areas of interest, and emerging trends in the field. Methods: Literature records and cited references were retrieved from the Web of Science Core Collection (WOSCC) database and analyzed using Excel 2019, Bibliometrix, VOSviewer, and CiteSpace. Based on the scientometric results, a stratified and focused thematic analysis was performed by cancer type to enhance clinical relevance and investigate tumor-specific applications. Results: A total of 2312 publications on 3D printing in cancer were identified, with the earliest published in 2006. Publications originated from 2740 institutions across 82 countries, with China leading the field with 779 articles. Sichuan University was the most prolific institution, publishing 75 articles. Frontiers in Oncology had the highest number of publications with 49 publications, while Biomaterials was the most frequently cited journal with 3354 citations. Contributions to the field have been made by 13 066 contributing authors, with Tu Chongqi having 39 publications being the most productive. Key research areas focus on utilizing 3D printing for preoperative planning and patient education in tumor surgery, treating malignant bone tumors, advancing tumor radiotherapy, constructing in vitro tumor cell models, and expanding 3D bioprinting applications in cancer therapy. Future directions may include developments in limb-salvage and prosthetic reconstruction, the use of 3D bioprinting tumor microenvironment (TME) models to investigate antitumor mechanisms, and applications of 3D printing in cancer drug resistance. Among the most frequently studied tumor types, research on malignant bone tumors has primarily focused on reconstruction and tissue regeneration. In breast cancer, key areas include surgical planning, radiotherapy bolus design, tumor microenvironment modeling, and drug delivery. Lung cancer studies have emphasized surgical simulation, imaging phantoms, and bioprinted tumor models, while cervical cancer research has concentrated on customized brachytherapy applicators and preclinical bioprinting platforms. Additional insights on liver, prostate, head and neck, colorectal cancers, and glioblastoma are provided in the supplementary tables to support targeted research efforts. Conclusions: This study provides a comprehensive overview of the global applications of 3D printing in cancer research from 2000 to 2024, analyzing contributions from various countries, institutions, authors, and journals, as well as key topics, keywords, and references. By incorporating cancer-type-specific thematic analysis, the study not only identifies global research patterns and hotspots but also delineates the translational progress and unmet clinical needs across major tumor types. The findings highlight current research hotspots and emerging trends, offering valuable insights for future advancements in the field.
- 4 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 1553-1579
Open AccessWorldwide research on 3D printing for cancer: a dual-method analysis of bibliometrics and stratified focused thematic
Aim: This study investigates the application of three-dimensional (3D) printing in cancer research and treatment, highlighting the current advancements, key areas of interest, and emerging trends in the field. Methods: Literature records and cited references were retrieved from the Web of Science Core Collection (WOSCC) database and analyzed using Excel 2019, Bibliometrix, VOSviewer, and CiteSpace. Based on the scientometric results, a stratified and focused thematic analysis was performed by cancer type to enhance clinical relevance and investigate tumor-specific applications. Results: A total of 2312 publications on 3D printing in cancer were identified, with the earliest published in 2006. Publications originated from 2740 institutions across 82 countries, with China leading the field with 779 articles. Sichuan University was the most prolific institution, publishing 75 articles. Frontiers in Oncology had the highest number of publications with 49 publications, while Biomaterials was the most frequently cited journal with 3354 citations. Contributions to the field have been made by 13 066 contributing authors, with Tu Chongqi having 39 publications being the most productive. Key research areas focus on utilizing 3D printing for preoperative planning and patient education in tumor surgery, treating malignant bone tumors, advancing tumor radiotherapy, constructing in vitro tumor cell models, and expanding 3D bioprinting applications in cancer therapy. Future directions may include developments in limb-salvage and prosthetic reconstruction, the use of 3D bioprinting tumor microenvironment (TME) models to investigate antitumor mechanisms, and applications of 3D printing in cancer drug resistance. Among the most frequently studied tumor types, research on malignant bone tumors has primarily focused on reconstruction and tissue regeneration. In breast cancer, key areas include surgical planning, radiotherapy bolus design, tumor microenvironment modeling, and drug delivery. Lung cancer studies have emphasized surgical simulation, imaging phantoms, and bioprinted tumor models, while cervical cancer research has concentrated on customized brachytherapy applicators and preclinical bioprinting platforms. Additional insights on liver, prostate, head and neck, colorectal cancers, and glioblastoma are provided in the supplementary tables to support targeted research efforts. Conclusions: This study provides a comprehensive overview of the global applications of 3D printing in cancer research from 2000 to 2024, analyzing contributions from various countries, institutions, authors, and journals, as well as key topics, keywords, and references. By incorporating cancer-type-specific thematic analysis, the study not only identifies global research patterns and hotspots but also delineates the translational progress and unmet clinical needs across major tumor types. The findings highlight current research hotspots and emerging trends, offering valuable insights for future advancements in the field.
- Open Access
- 30 January 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-17
Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined. We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.go and randomised controlled trials (RCTs) from major international conferences for literature related to neoadjuvant immunotherapy combinations published as first-line treatment options for non-small cell lung cancer from the start of the library to 20 February 2024, and performed a systematic review and network meta-analysis. We analyzed nine studies involving 3431 patients, including eight perioperative neoadjuvant immunotherapy combinations for non-small cell lung cancer. For patients without programmed death-ligand 1(PD-L1) selection, Toripalimab plus chemotherapy provided the best Pathological complete response (PCR) benefit (OR = 32.89,95% CI:7.88-137.32), best Major Pathological response (MPR) benefit (OR = 10.25, 95% CI: 5.81–18.10) and best Event-free survival (EFS) benefit (HR = 0.40,95% CI: 0.28–0.57). Nivolumab plus chemotherapy provided the best surgical resection rate (OR = 1.71, 95% CI:0.87–3.40) and pembrolizumab plus chemotherapy provided the best R0 surgical resection rate (OR = 2.20, 95% CI:1.28–3.79). In contrast, the combination of ipilimumab, nivolumab and chemotherapy, and the combination of toripalimab and chemotherapy were associated with the lowest incidence of adverse events of grade 3 or above during neoadjuvant therapy. Our findings suggest that: Toripalimab plus chemotherapy showed better neoadjuvant efficacy and may have an overall survival benefit, but also increased the incidence of serious adverse events during neoadjuvant therapy.
- 30 January 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-17
Open AccessComparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined. We searched PubMed, EMBASE, Cochrane Library, ClinicalTrials.go and randomised controlled trials (RCTs) from major international conferences for literature related to neoadjuvant immunotherapy combinations published as first-line treatment options for non-small cell lung cancer from the start of the library to 20 February 2024, and performed a systematic review and network meta-analysis. We analyzed nine studies involving 3431 patients, including eight perioperative neoadjuvant immunotherapy combinations for non-small cell lung cancer. For patients without programmed death-ligand 1(PD-L1) selection, Toripalimab plus chemotherapy provided the best Pathological complete response (PCR) benefit (OR = 32.89,95% CI:7.88-137.32), best Major Pathological response (MPR) benefit (OR = 10.25, 95% CI: 5.81–18.10) and best Event-free survival (EFS) benefit (HR = 0.40,95% CI: 0.28–0.57). Nivolumab plus chemotherapy provided the best surgical resection rate (OR = 1.71, 95% CI:0.87–3.40) and pembrolizumab plus chemotherapy provided the best R0 surgical resection rate (OR = 2.20, 95% CI:1.28–3.79). In contrast, the combination of ipilimumab, nivolumab and chemotherapy, and the combination of toripalimab and chemotherapy were associated with the lowest incidence of adverse events of grade 3 or above during neoadjuvant therapy. Our findings suggest that: Toripalimab plus chemotherapy showed better neoadjuvant efficacy and may have an overall survival benefit, but also increased the incidence of serious adverse events during neoadjuvant therapy.
- Open Access
- 15 June 2024
- Published by Elsevier in Phytomedicine
- Vol. 132, 155831
Lung-intestinal axis, Shuangshen granules attenuate lung metastasis by regulating the intestinal microbiota and related metabolites
- 15 June 2024
- Published by Elsevier in Phytomedicine
- Vol. 132, 155831
Open AccessLung-intestinal axis, Shuangshen granules attenuate lung metastasis by regulating the intestinal microbiota and related metabolites
- 8 May 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155690
Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma
- 8 May 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155690
Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma
- 1 December 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 281, 113305
Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition
- 1 December 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 281, 113305
Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition
- Open Access
- 28 December 2020
- Published by Springer Nature in Research Square
A Network Pharmacology Approach to Determine the Mechanisms of Action of Shuangshen Granules in Suppressing Pancreatic Cancer Precursor Lesions
Background and purpose: Pancreatic cancer is an insidious and highly lethal disease. Recognition and treatment of pancreatic cancer precursor lesions (PCPL) are important measures and can improve patient survival rate. Shuangshen Granules (SSG) have been prescribed for use in clinical practice for more than seven years and are widely used to treat the precursor lesions of various tumours. In this study, we used network pharmacology to explore the pharmacological mechanisms through which SSG suppress PCPL. We aimed to provide a basis for further research and the development of small, molecular, natural chemical drugs.Methods: We first searched databases and screened the bioactive components of SSG and the related targets acting on PCPL to construct a component-target network. Then, network topology analysis was used to analyse the hub target of SSG acting on PCPL. Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were also performed to determine the potential pathways. Finally, molecular docking simulations were carried out to investigate the interactions between PCPL-target proteins and the active components of SSG.Results: Seven of the main components of SSG affected PCPL, with 100 key targets including 16 hub targets. In addition, GO and KEGG enrichment analysis revealed that SSG regulated 111 molecular functions, 46 cellular components, 2334 biological processes, and 144 related signalling pathways, of which 26 were closely related to PCPL. Results of molecular docking analysis showed that the PCPL-related targets had strong binding properties with the active components of SSG, quercetin, and ginsenoside rh2, mainly TNF, IL-6, AKT1, TP53, and EGFR.Conclusion: This study has revealed the pharmacological and molecular mechanisms through which SSG acts on PCPL. It also provides powerful evidence to support the exploration of the pharmacological mechanisms of action and clinical applications of traditional Chinese medicine.
- 28 December 2020
- Published by Springer Nature in Research Square
Open AccessA Network Pharmacology Approach to Determine the Mechanisms of Action of Shuangshen Granules in Suppressing Pancreatic Cancer Precursor Lesions
Background and purpose: Pancreatic cancer is an insidious and highly lethal disease. Recognition and treatment of pancreatic cancer precursor lesions (PCPL) are important measures and can improve patient survival rate. Shuangshen Granules (SSG) have been prescribed for use in clinical practice for more than seven years and are widely used to treat the precursor lesions of various tumours. In this study, we used network pharmacology to explore the pharmacological mechanisms through which SSG suppress PCPL. We aimed to provide a basis for further research and the development of small, molecular, natural chemical drugs.Methods: We first searched databases and screened the bioactive components of SSG and the related targets acting on PCPL to construct a component-target network. Then, network topology analysis was used to analyse the hub target of SSG acting on PCPL. Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were also performed to determine the potential pathways. Finally, molecular docking simulations were carried out to investigate the interactions between PCPL-target proteins and the active components of SSG.Results: Seven of the main components of SSG affected PCPL, with 100 key targets including 16 hub targets. In addition, GO and KEGG enrichment analysis revealed that SSG regulated 111 molecular functions, 46 cellular components, 2334 biological processes, and 144 related signalling pathways, of which 26 were closely related to PCPL. Results of molecular docking analysis showed that the PCPL-related targets had strong binding properties with the active components of SSG, quercetin, and ginsenoside rh2, mainly TNF, IL-6, AKT1, TP53, and EGFR.Conclusion: This study has revealed the pharmacological and molecular mechanisms through which SSG acts on PCPL. It also provides powerful evidence to support the exploration of the pharmacological mechanisms of action and clinical applications of traditional Chinese medicine.